Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma

Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma

Abstract Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective for EGFR-mutant lung adenocarcinoma (LUAD), resistance inevitably develops through diverse mechanisms, including secondary genetic mutations, amplifications and as-yet undefined processes. To comprehensively unravel the mech...

Full description

Saved in:
Bibliographic Details
Main Authors: Taro Shinozaki, Kazuhiro Togasaki, Junko Hamamoto, Akifumi Mitsuishi, Takahiro Fukushima, Kai Sugihara, Toshiki Ebisudani, Masahiko Okada, Ayaka Saito, Lisa Shigematsu, Hatsuyo Takaoka, Fumimaro Ito, Keiko Ohgino, Kota Ishioka, Kageaki Watanabe, Tsunekazu Hishima, Yutaka Kurebayashi, Katsura Emoto, Hideki Terai, Shinnosuke Ikemura, Ichiro Kawada, Keisuke Asakura, Tomoyuki Hishida, Hisao Asamura, Yuki Ohta, Sirirat Takahashi, Mayumi Oda, Megumu Saito, Mami Matano, Kenzo Soejima, Masayuki Fujii, Koichi Fukunaga, Hiroyuki Yasuda, Toshiro Sato
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-59623-3
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective for EGFR-mutant lung adenocarcinoma (LUAD), resistance inevitably develops through diverse mechanisms, including secondary genetic mutations, amplifications and as-yet undefined processes. To comprehensively unravel the mechanisms of EGFR-TKI resistance, we establish a biobank of patient-derived EGFR-mutant lung cancer organoids, encompassing cases previously treated with EGFR-TKIs. Through comprehensive molecular profiling including single-cell analysis, here we identify a subgroup of EGFR-TKI-resistant LUAD organoids that lacks known resistance-related genetic lesions and instead exhibits a basal-shift phenotype characterized by the hybrid expression of LUAD- and squamous cell carcinoma-related genes. Prospective gene engineering demonstrates that NKX2-1 knockout induces the basal-shift transformation along with EGFR-target therapy resistance. Basal-shift LUADs frequently harbor CDKN2A/B loss and are sensitive to CDK4/6 inhibitors. Our EGFR-mutant lung cancer organoid library not only offers a valuable resource for lung cancer research but also provides insights into molecular underpinnings of EGFR-TKI resistance, facilitating the development of therapeutic strategies.
ISSN:2041-1723

Similar Items